Imprimis Pharmaceuticals reported a net loss of $2.5 million, or $0.12 per share, in the third quarter of 2018 compared with a net loss of $5.7 million, or $0.28 per share, in the third quarter of 2017.
Revenues increased 66% to $10.7 million, while ophthalmology revenue increased 81% to $8.9 million, according to a press release.
Selling, general and administrative expenses increased from $5.8 million to $7 million for the quarter, and research and development expenses increased from $63,000 to $233,000.
Uncategorized